Withersworldwide的动态

"Can the UK's life sciences sector secure the funding it needs?" Our COO and Co-Founder, Daniel Rooke, recently contributed to an article with Susanna Stanfield and Withersworldwide to discuss concerns around the support needed to help the UK maintain its leading position in the life sciences sector. In the article, Dan offers his advice to founders to reassure investors: “The key challenges tend to be around the robustness of the underlying business (i.e., how you will make money) and people (who will you recruit, when and why). Founders need to think carefully about these issues, plan appropriately and be aware that it will likely take time to raise capital.” To read the full article, visit: https://lnkd.in/dPEEreQH #StartUps #VentureCapital #LifeSciences #Investors

Great to contribute to this article with Susanna Stanfield and Withersworldwide on the poignant topic of is the UK at risk of losing its edge in global life sciences. Thanks for the invite! #lifesciences #innovation #keepingasharpedge #uk

Did you miss #AAI2024? Read our blog and catch up on our flow news

Our #50color flow cytometry panel is out now as a peer-reviewed open access article in Cytometry Part A, the journal of the International Society for Advancement of Cytometry. If you are into high-dimensional cytometry, please have a look here: https://lnkd.in/eGXTrURj Figure 1 shows you how the data looks like, but the exciting details are all in the supplementary material, describing our step-by-step process how we got to the final panel, and the new metric of unmixing-spreading error. Check it out! Also, there is an accompanying commentary summarizing our work: https://lnkd.in/eH-w-sAM This panel has been done by Andrew Konecny in the lab of Martin Prlic at the Fred Hutch, together with our brilliant collaborators Aaron J. Tyznik, and Peter Mage - thank you all! Cannot wait to establish the same technologies for the life science community here at ETH Zürich. #flowcytometry #50color #immunology #FACSDiscoverS8 #collaboration #humanimmunology #paneldesign

?? Groundbreaking Achievement in Science! ??? Scientists have created the first mouse model with a complete, functional human immune system. This innovation bridges the gap between preclinical research and human trials, providing better insights into human immunology and disease. Key Benefits: Accurate Research: Improved studies of human immune responses. Enhanced Drug Testing: Better evaluation of new treatments. Personalized Medicine: Tailored therapies based on individual immune responses. This breakthrough is set to revolutionize medical research and accelerate the development of next-generation therapies. Stay tuned for more updates! #MedicalResearch #Immunology #ScientificBreakthrough

Did you know the first Human Challenge Trial dates back to 1796 when English surgeon Edward Jenner tested the world’s first vaccine? ?? Jenner exposed his gardener’s 8-year-old son to cowpox and then smallpox, pioneering the field of immunology. Since then, human challenge trials have evolved significantly, supported by the highest ethical standards, HCT's have been instrumental in studying dozens of diseases. ?? Human challenge trials continue to play a crucial role in advancing medical research by providing early proof of concept - at hVIVO we are proud to play a leading role in accelerating the drug development process. #HVO #CHIM #HumanChallenge #DrugDevelopment #ClinicalTrials

It's almost time for this year's Multiplex Image Analysis workshop by the La Jolla Institute for Immunology and the Quantitative Bioimaging Society! We look forward to seeing you at our table and discussing your projects and how AI-powered quantitative image analysis with HALO can help you extract more data from your multiplex images! #DigitalPathology #MultiplexedImaging #ImageAnalysis #TissueAnalysis #HALOai #IndicaLabs

You can also discuss about your projects on Singlecell multiomics and discover our latests kits #singlecell #transcriptomic #genomic

Come on by and see Simon and myself to discuss how MPX can help your research.

OSE Immunotherapeutics just announced a partnership with Scienta Lab to leverage their AI platform, EVA, in our precision immunotherapy work. Scienta Lab's AI model has been specifically developed for chronic inflammation, and this is a perfect fit for our work right now. What it means, is that we can potentially develop treatments that are more tailored to each patient’s specific needs. And that in turn, could lead to better health outcomes. Since joining the biotech world, I’ve seen the urgency and agility that drive our industry. Partnerships like this one with Camille Bouget, Vincent Bouget and their team truly embody that spirit. #PrecisionMedicine #AI #Immunotherapy #BetterHealth #BiotechInnovation Nicolas Poirier Aurore Morello Isabelle Girault